

## Study: ENGOT-ov79 / REFRAme-O1

REFRAme-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator's Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha. (FOLR1)

### MaNGO Sites:

Prov	City	Site	Principal Investigator	Active **
BS	Brescia	Spedali Civili	Germana Tognon	
LC	Lecco	Ospedale Manzoni	Federica Villa	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
MO	Modena	AOU Modena	Roberto Sabbatini	
PD	Padova	Istituto Oncologico Veneto	Giulia Tasca *	
PR	Parma	AOU Parma	Angelica Sikokis	
RM	Roma	Ospedale Umberto I	Federica Tomao	
TO	Torino	Ospedale Sant'Anna	Dionyssios Katsaros	
MO	Modena	Policlinico di Modena	Roberto Sabbatini	R

\* MaNGO Principal Investigator

\*\* MaNGO sites list: to be confirmed by Sponsor

**R: backup site**